Description:

HAON are developing CanVas-001, a potential world first therapeutic drug for newborn brain injury. Our lead indication for CanVas-001is one of the largest global unmet needs, hypoxic ischemic encephalopathy (HIE). HIE is brain injury due to decreased brain oxygenation around birth. HIE causes 22% of infant deaths and 30% of cerebral palsy with no approved therapies. HAON’s proprietary CanVas platform can unlock paradigm-shifting treatments for a range of neurologic and other serious diseases including rare blood disorders. CanVas is powered by endothelial colony forming cells (ECFCs) and mesenchymal stromal cells (MSCs).